Navigation Links
Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors
Date:2/25/2013

BALTIMORE, Feb. 25, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company, today announced the appointment of Incyte Corporation President and Chief Executive Officer Paul A. Friedman, M.D., to its Board of Directors. Dr. Friedman, a seasoned pharmaceutical industry executive with strong experience in management of R&D and corporate functions, joins Gliknik's board as the company is continuing to advance its pipeline of drug candidates targeting various cancers and immune disorders.

"It's an honor for us to welcome Paul to the Gliknik Board of Directors," said Gliknik CEO David S. Block. "His deep experience in pharmaceutical research, development, commercialization, and business development and his unwavering commitment to excellence bring an important perspective to Gliknik as we seek to advance and to partner our pipeline of novel therapies."

Dr. Friedman joined Incyte in 2001 as Chief Executive Officer and a Director. A biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation, Incyte developed and commercialized Jakafi® (ruxolitinib) under Dr. Friedman and has a robust product pipeline. Previously, Dr. Friedman served as President of R&D for the DuPont Merck Pharmaceutical Company, President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman is also a director of Auxilium Pharmaceuticals, Inc.

"I welcome the opportunity to join the Gliknik Board of Directors and look forward to contributing to its goal of advancing and partnering the company's clinical immunomodulator and preclinical stradomer™ programs," said Dr. Friedman.

About Gliknik Inc.
Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. In addition to the stradomer program for autoimmune diseases, Gliknik also has commercial rights to two cancer immunomodulator drugs that are in multiple-dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma. Learn more at www.gliknik.com.


 


'/>"/>
SOURCE Gliknik Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
2. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
3. Nephros Appoints John C. Houghton as President and Chief Executive Officer
4. Herb Baer Appointed President of Polar USA
5. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
11. Millstone Medical Outsourcing Hires New Vice President Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... FLINT, Mich. , April 28, 2016 /PRNewswire/ ... transaction . Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... it has signed a definitive agreement to acquire ... Advanced Specialty Pharmacy ("TNH"), a leading specialty pharmacy ... Van Nuys, California . In 2015, ...
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... Dr. Vivek Ahuja , George ... phen Schmidt Join the Growing Organization ... for life sciences, today announced key new leaders have joined the ... a growing business.  This will bolster the company,s safety business unit ... ArisGlobal in the position of Vice President - Safety. George has ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Registration is now open for the 31st annual AIDS Walk ... Hatch Memorial Shell on the Esplanade. The event regularly draws thousands of participants, making it ... competitive, timed event fully sanctioned by the USA Track & Field Association. , The ...
(Date:5/3/2016)... ... 2016 , ... Elizabeth Murray has always loved walking one to two miles ... her shoulder and one on her arm. But she got to the point where ... valve prolapse. , The valves of the heart wouldn’t close properly resulting in mitral ...
(Date:5/3/2016)... ... 03, 2016 , ... Empyrean Benefit Solutions, Inc., the Hi-Touch ... center in La Vergne, Tennessee, near Nashville. The new center will complement Empyrean’s ... client services. , “Our Nashville-area center allows us to achieve several goals,” said ...
(Date:5/3/2016)... ... 03, 2016 , ... Ogawa World USA introduced the first of its kind ... exclusive Smart Application. The Smart 3D combines the best in technological advancement, design, and ... profile and specialized massage program, each user has a tailored experience unparalleled by any ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic dentist in ... both new and existing patients. Cosmetic dentistry allows patients to improve the aesthetics of ... smiles with some minor or more serious cosmetic flaws. These specials allow patients to ...
Breaking Medicine News(10 mins):